Drug Trial Radar · NCT07446855
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Mar 17, 2026
Primary completion
Mar 29, 2030
Study completion Mar 29, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
Conditions
- Solid Tumours
Interventions
AZD4956Drug
AZD4956 will be administered orally.
SaruparibDrug
Saruparib will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From Screening (Day -28) to follow-up (up to 3.5 years)
- Part B: Progression free survival (PFS)Time frame: Up to 3.5 years
- Part A - Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to 28 days
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
New York, New York · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Fairfax, Virginia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Westmead, Australia · Recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Barcelona, Spain · Not yet recruiting
Research Site
Logroño, Spain · Not yet recruiting
Research Site
Pozuelo de Alarcón, Spain · Not yet recruiting
Research Site
Seville, Spain · Not yet recruiting
Research Site
Cambridge, United Kingdom · Recruiting
Research Site
London, United Kingdom · Not yet recruiting
Research Site
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.